Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 17/20 | 1.00 |
| ▸ | MAPK7 | Q13164 | 17/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 13/20 | 1.00 |
| ▸ | BRD4 | O60885 | 4/20 | 0.86 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.86 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.86 |
| ▸ | DCLK2 | Q8N568 | 2/20 | 0.86 |
| ▸ | GAK | O14976 | 1/20 | 0.86 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.71 |
| ▸ | PLK4 | O00444 | 1/20 | 0.71 |
| ▸ | PI4KA | P42356 | 1/20 | 0.71 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.71 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.71 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.71 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.71 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17721095 | 0.92 | LRRK2 (0.87) | LRRK2MAPK7DCLK1BRD4TNK2 | |
| SCHEMBL618262 | 0.92 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4TNK2 | |
| SCHEMBL29360090 | 0.92 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4TNK2 | |
| SCHEMBL31092834 | 0.92 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4TNK2 | |
| SCHEMBL17721080 | 0.91 | LRRK2 (0.86) | LRRK2MAPK7DCLK1BRD4TNK2 | |
| SCHEMBL10098768 | 0.91 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4TNK2 | |
| SCHEMBL618577 | 0.90 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4TNK2 | |
| SCHEMBL616301 | 0.87 | LRRK2 (1.00) | LRRK2MAPK7DCLK1BRD4TNK2 | |
| SCHEMBL23144737 | 0.86 | LRRK2 (0.80) | LRRK2MAPK7DCLK1BRD4TNK2 | |
| SCHEMBL29850674 | 0.86 | LRRK2 (0.80) | LRRK2MAPK7DCLK1BRD4TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034132-B1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA FARBER CANCER INST INC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| EP-4034132-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021061894-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-9464091-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2014145909-A2 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | LRRK2 324/4885MAPK7 292/4885DCLK1 483/4885 |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | LRRK2 364/4885MAPK7 263/4885DCLK1 480/4885 |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | LRRK2 324/4885MAPK7 292/4885DCLK1 483/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | LRRK2 324/4885MAPK7 292/4885DCLK1 483/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | LRRK2 340/4885MAPK7 253/4885DCLK1 453/4885 |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | LRRK2 340/4885MAPK7 253/4885DCLK1 453/4885 |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | LRRK2 324/4885MAPK7 292/4885DCLK1 483/4885 |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | LRRK2 324/4885MAPK7 292/4885DCLK1 483/4885 |
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | OXSR1, MAPK1, NGFR | LRRK2 340/4885MAPK7 30/4885DCLK1 2710/4885 |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | MAPKAPK5, DUSP5, MAP3K5 | LRRK2 427/4885MAPK7 60/4885DCLK1 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.